Investors

Event Calendar

 

Upcoming Events

Obseva 2023 Swiss Annual Report: 30 April, 2024

Read more


    Annual General Meeting: Thursday 27 June, 2024

    Venue: TBC // Registration Deadline: Thursday 13 June 2024
    Read more


      Half Year 2024 Financial Results: 30 September 2024

      Read more


        Past Events

        Bio€quity Europe 2016

        May 10, 2016

        Read more

        15th Annual Needham Healthcare Conference

        April 12, 2016

        Read more

        8th Annual Sofinnova Japan Biopharma Partnering Conference – Tokyo, Japan

        October 27, 2015

        Read more
        1 29 30 31 32

        General Meetings

        ObsEva Annual General Meeting 2023

        June 29, 2023

        Read more

        ObsEva Annual General Meeting 2022

        May 18, 2022

        Read more
        1 2 3 4
         
         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue